Infections with herpes simplex virus type 2 (HSV-2) are a
No licensed HSV vaccine is currently available to protect against the disease consequences of HSV, but a number of major public health problem and continue to escalate despite effective antiviral therapy (reviewed by Whitley [1] ). The approaches are undergoing preclinical and clinical evaluation. These include polynucleotide and subunit vaccine strategies, unique ability of HSV to colonize the sensory ganglia, establish a latent infection, and spontaneously reactivate to produce seriusing 1 or 2 of the 11 currently recognized envelope glycoproteins, and live attenuated approaches, using viruses carrying ous recurrent disease as well as asymptomatic shedding has deletions in genes essential and nonessential for growth in exacerbated this problem to epidemic proportions. Disease contissue culture systems [2, 6, 7] . The concerns surrounding the sequences can include lesions on the genital mucosa, infections development of a live viral vaccine for HSV are mainly safety of the neonate in the birthing process, progressive herpesvirus issues revolving around the potential for reactivation from lainfections in the immunocompromised, and in some cases entency, recombination with wild-type virus, and the oncogenic cephalitis. In the United States alone, it is estimated that potential of viral DNA [2] . As shown by the development of Ç500,000 -1 million new cases of genital herpes arise annually a successful vaccine for varicella-zoster virus (VZV), these [2] . Although neonatal herpes infection is relatively rare by concerns, while valid, are balanced by the clear benefits afcomparison, amounting to Ç1500 cases annually [3] , it is estiforded by this herpesvirus vaccine. mated that Ç20,000 precautionary cesarean deliveries are done As the precise measurable immune parameters that should each year to prevent the high infant mortality associated with be primed to prevent disease are unknown, live attenuated viral the infection.
vaccines have many clear advantages. They provide a vehicle Minimizing the replication of the virus at the initial site of for complete presentation of all viral antigens to the host's infection to reduce the incidence and severity of recurrent disimmune system, stimulating both humoral and cell-mediated ease may be achievable through vaccination. The rationale that immune responses. They can be efficiently propagated with a vaccine directed against HSV could be effective is strengthease and are therefore extremely cost-effective vaccines. Live ened by the observations that individuals with prior exposure to attenuated viruses have also been successful at combating myr-HSV-1 infections usually experience milder primary infections iad human viral diseases, as exemplified by the vaccines for with HSV-2 [4] and that reinfection by another type 2 strain smallpox, polio, mumps, measles, rubella, and very recently is uncommon in immunocompetent individuals [5] .
chicken pox, which is caused by another member of the herpesvirus family, VZV [2, 8, 9] . Experiments with recombinant HSV-1 deletion viruses have identified several genes that are required for efficient viral g 1 34.5 deletion mutant was also significantly reduced relative 7 .2], 0.006 M sodium glutamate, 1% human serum albumin).
to wild-type HSV [13, 16] .
Purification and analyses of viral DNA. Viral DNA intended
In this report, we describe the construction and characterizafor transfections was prepared from NaI gradients as described tion of a genetically engineered HSV-2 strain G -based recom- [32] ; otherwise, viral DNA was purified by phenol-chloroform binant virus (RAV 9395) designed to function as a live attenuextraction from cytoplasmic extracts of infected Vero or MRC-5 ated HSV-2 vaccine. This recombinant virus carries deletions cells. The viral DNA was analyzed by the method of Southern in the UL55 and UL56 genes as well as both copies of the [ into PUC8 [36] . Both plasmids were gifts from B. Roizman. The Vero and rabbit kidney (RK) cells were used to isolate virus from deletions engineered into the tk, UL55, UL56, and g 1 34.5 genes biologic specimens. All cell lines except MRC-5 were maintained were originally based on homology with the available published in MEM (JRH Biosciences, Lenexa, KS) supplemented with 10% sequences from other HSV-2 strains [37, 38] . All deletions were fetal bovine serum (FBS; JRH Biosciences), L-glutamine (2 mM), verified by DNA sequencing. penicillin (100 U/mL), streptomycin (0.1 mg/mL), and pyruvate Antibodies. Polyclonal antibodies to the UL56 protein were (1 mM). MRC-5 cells were maintained in Dulbecco's modified prepared to a GST fusion protein as described elsewhere (unpubEagle medium (JRH Biosciences) plus 10% fetal calf serum and lished data). Monoclonal antibody specific for HSV-2 glycoprotein supplemented as above. For selection of tk / viruses, the medium gD was a gift from B. Roizman. was supplemented with 1.1 1 10 04 M hypoxanthine, 4.5 1 10
07
PAGE and immunoblotting. Cell monolayers were infected M aminopterin, and 2 1 10 05 M thymidine (HAT; Sigma, St with the appropriate virus at an MOI of 5, and at 17 h after Louis). For tk 0 virus selection, the medium was supplemented infection, cells were harvested. The infected cell monolayers were with 40 mg/mL bromodeoxyuridine (Sigma). To pick plaques, the washed, scraped into cold PBS, and centrifuged to pellet the cells. overlay medium was supplemented with human immune globulin
The cell pellets were disrupted by addition of 350 mL of PBS A* (Miles, Elkhart, IN) at 0.1 mL/100 mL of medium. Transfections (PBS containing 1% NP-40, 1% sodium deoxycholate, 10 mM for the selection of recombinant viruses were done in rabbit skin tosylsulfonyl phenylalanyl chloromethyl ketone, 10 mM a-tosylcells as previously described [29] , and the resulting recombinants L-lysine chloromethyl ketone, 5 mM phenylmethylsulfonyl fluowere routinely plaque-purified twice under selection on 143 cells ride, 1 mg/mL pepstatin, and 17 mg/mL aprotinin). The proteins and twice on Vero cells.
were electrophoretically separated in denaturing 10% polyacryl-HSV-2(G) was a gift from B. Roizman (University of Chicago) amide gels and transferred to nitrocellulose. After transfer, the and its properties are reported elsewhere [30, 31] . Recombinant membrane was blotted with the appropriate antisera, as described previously [39] . virus stocks were stabilized by the addition of 9% sterile skim 
NcoI collapse of pAV24 deletes Ç0.4 kbp* of UL56 gene pAV24 pAV24 pAV27
1.7-kbp a27tk inserted at NcoI sites of pAV24 pRB3968 pAV24 pAV49
NcoI-BsgI collapse of pAV26 deletes Ç1.3 kbp,* pAV26 pAV26 including all UL56 and 80% of UL55 sequence * Sizes based on actual sequence determined for HSV-2(G) (Cha TA, unpublished data).
Studies in guinea pigs. Female Hartley guinea pigs were obin 0.5 increments as previously described [27] . Lesion score-day AUC and peak lesion scores were calculated. tained from Charles River Breeding Laboratories (Raleigh, NC)
Assay for latent virus. At the termination of each experiment, and randomly assigned into several groups. The guinea pigs were the lumbosacral ganglia were removed from both sides of the free of HSV neutralizing serum antibodies at the time of inoculaspinal cord of 6 animals from each of the study groups and cocultition. Viral inoculation was accomplished intravaginally (ivag), by vated onto confluent RK cells. Cultures with positive viral cytoinsertion of a Dacron-tipped swab soaked with virus into the vagipathic effect were verified by further passage, and the identity of nal tract and rotating six times, or intramuscularly (im), by injecthe virus was deduced by restriction enzyme analyses of the viral tion of virus into the bicep femoris muscle of the right hind leg.
DNA and confirmed by Southern analysis. The titer of each inoculum was verified by titration on Vero cells.
Statistical evaluation. Peak lesion scores, peak virus titers, The site of inoculation was shaved and monitored for signs of virus titer-day AUC, and lesion score-day AUC were compared inflammation. Blood samples were taken from all animals 1 day between immunized and nonimmunized animals using the Mannbefore immunization, before inoculation with the challenge virus, Whitney U rank sum test. P £ .05 was considered significant. and at the termination of each study to determine the HSV neutralizing antibody titers. All animals were examined daily to determine the severity and duration of primary genital lesions for 28 days after immunization, and the observations were continued for 
also (data not shown). RAV 9364 was constructed by cotrans-
The serum was collected, and neutralization titers were determined fection of rabbit skin cells with tk deletion plasmid pAV14, by plaque reduction assays on Vero cells. Development and severity of genital lesions were followed and graded on a 0.0-5.0 scale along with intact plaque-purified HSV-2(G) DNA. Following 
pAV27. Tk / progeny viruses were selected and plaque-purified. Viruses were screened for the insertion of the a27tk gene by a 1.2-kbp increase in HSV-2(G) BamHI F fragment (figure transfection, tk 0 viruses were selected using 5-bromo-2-deoxyuridine. The 498-bp deletion in RAV 9364 eliminates a 1B), and the resulting tk / recombinant was designated RAV 9391 (figure 2, line 7). RAV 9394, a tk 0 parent virus of RAV BamHI restriction enzyme site and results in the fusion of HSV-2(G) BamHI N (Ç4 kbp) and BamHI DS (Ç3.2 kbp).
9395, was constructed by cotransfection of RAV 9391 with pAV49, a plasmid carrying deletions engineered in the UL55 Recombinant viruses were screened with Southern blots by detecting the increase in size of BamHI S from 3.6 to and UL56 genes. The resulting recombinant carried an additional 1336-bp deletion encompassing all of the UL56 ORF 7.6 kbp using pAV20 (figure 1C). To engineer deletions or introduce modifications into the g 1 34.5 gene, RAV 9365, and 80% of the UL55 ORF. Finally, the tk gene was restored to the tk locus, together with the UL24 ORF on the opposite which carried two copies of the HSV-1(F) tk gene driven by the HSV-1(F) a27 promoter (a27tk) inserted in both copies strand by cotransfection of pAV9 with RAV 9394 DNA and selection of tk/ viruses to generate RAV 9395 (figure 2, of the g 1 34.5 gene within the HSV-2(G) genome (figure 2, line 5), was prepared. RAV 9365 was constructed by line 8)
The final vaccine candidate construct, designated RAV 9395, cotransfection of rabbit skin cells with RAV 9364 DNA and pAV16. Tk / recombinant viruses were screened according was specifically designed to eliminate the expression of ICP34.5 and the ORFs antisense to the g 1 34.5 gene, together to the presence of the a27tk gene in BamHI V and BamHI G (UV) by Southern hybridization using both nick-translated with the proteins encoded by genes UL55 and UL56. The deletions were all verified by nucleic acid sequencing. Finally, tk containing plasmid pRB3968 to confirm insertion of the tk gene and plasmid pAV2 to detect the increase in size of the tk gene in recombinant virus RAV 9395 was restored and shown to be intact ( figure 1C ) and functional (data not shown). the BamHI V and G by 700 bp due to the insertion (figure 1A). Recombinant virus RAV 9366, containing a 923-bp RAV 9395 shares many of the properties previously reported for HSV-1 g 1 34.5 deletion virus R3616, in that host shut-off deletion in both copies of the g 1 34.5 gene, was generated by cotransfecting intact RAV 9365 viral DNA with pAV15 of protein synthesis was observed in neuroblastoma cell lines [44] , indicative of the inability of this recombinant to express (figure 2, line 6). In this plasmid, nearly all of the coding sequence of the g 1 34.5 gene had been deleted. Tk 0 recombia fully functional ICP34.5 protein (data not shown). To test the ability of RAV 9395 to express UL56 protein, infected cell nant viruses were selected. The expected genomic structure was confirmed by hybridization of electrophoretically sepalysates were prepared and analyzed by Western blots, using a polyclonal antibody raised against a GST-UL56 fusion protein rated restriction enzyme digests of viral DNA with radiolabeled pAV2, a probe that contains the g 1 34.5 gene (table 1, as a probe. In cells infected with HSV-2(G) or RAV 9381, a recombinant virus in which a deleted UL56 gene was repaired figure 1A ).
When constructing a recombinant virus for use as a live with wild-type sequences, the UL56 protein was detected as a series of polypeptides with an apparent mobility ranging in attenuated vaccine, it is possible to overattenuate the virus, which could possibly negate its value as a vaccine. To minimize size from 25 to 30 kDa. ( figure 3, lanes 2, 6) . Subsequent studies have indicated that the multiple forms of the UL56 this possibility, a gradation of additional deletions were introduced into RAV 9366. The choice of genes to delete was based protein arise from differential phosphorylation (unpublished data). None of the UL56 isoforms could be detected in lysates on several observations: (1) R7020, a prototype live, attenuated, genetically engineered vaccine for HSV, contained deletions of cells infected with RAV 9393 ( figure 3, lane 4) , in which 50% of the UL56 gene was deleted, or vaccine candidate RAV in UL55 and UL56 [23] ; (2) the avirulent phenotype of HFEM, Figure 1 . Phosphor images of Southern blot analyses of structure of HSV-2 wild-type and RAV recombinant viruses. BamHI digests of viral DNA were electrophoretically separated on 0.8% agarose gels, transferred to nylon membranes, and hybridized with specific radiolabeled probes. A, Viral DNA was probed with radiolabeled pAV2, which contains g 1 34.5 gene -specific sequences together with flanking sequences. BamHI V and BamHI UV fragments are shown. Multiple banding pattern obtained is due to heterogeneity of viral ''a'' sequences, which are labeled with this probe. B, Viral DNA was probed with radiolabeled pAV23. pAV23 contains HindIII O fragment of HSV-2(G) DNA and hybridizes to BamHI F fragment, which contains UL55 and UL56 genes. BamHI F fragment is indicated. C, Viral DNA was probed with radiolabeled pAV20, a clone containing sequences from HSV-2 tk gene and its flanking sequences. BamHI S and new band (BAM DS/N) at Ç7.2 kb due to fusion of BamHI N with deleted form of BamHI S are indicated.
9395, which has a large 1.3-kbp deletion spanning the entire levels of viral replication in the vagina, and severe genital lesions in 90% of the animals. This dose was therefore used UL56 gene and 80% of the UL55 gene ( figure 3, lane 5) . As a control for equal infectivity, the blot was further probed with as the inoculating dose of HSV-2(G) in all subsequent studies. RAV 9395 virulence study. The second set of experiments a monoclonal antibody specific for HSV-2(G) gD. The gD protein could be readily detected at equivalent intensities in all was designed to compare the virulence of recombinant virus RAV 9395 with HSV-2(G). Two groups of 15 guinea pigs, infected cell lysates.
Virus dose-ranging study. The first series of experiments each weighing 500 g, were inoculated ivag with either 1 1 10 6 pfu of RAV 9395 or 1 1 10 5 pfu of HSV-2(G). Replication were designed to determine the optimal HSV-2(G) dose to produce genital disease in ú90% of the guinea pigs. Three of the virus was monitored by determining the titer of RAV 9395 and HSV-2(G) recovered from vaginal swabs taken on groups of 10 guinea pigs, each weighing 500 g, were inoculated ivag with 5 1 10 4 , 1 1 10 5 , or 5 1 10 5 pfu of HSV-2(G). days 1, 3, 5, 7, and 10 and twice weekly thereafter until termination of the study. The animals were monitored daily for the Replication of HSV-2(G) in the vaginal vault was determined by testing vaginal swabs for infectious virus 1, 3, 5, 7, and 10 severity and duration of genital lesions for 28 days. Any recurrences of genital lesions were monitored for an additional 28 days after inoculation and then twice weekly. The guinea pigs were also monitored daily for the presence and severity of days. Blood samples were obtained from all animals before inoculation, on postinoculation day 27, and at the termination genital lesions for 28 days after inoculation (table 3) . Infectious virus was recovered from all animals in the study. Except for of the study (day 56) to determine the production of HSV neutralizing antibody. As shown in table 4, the titer of virus 2 animals in the lower dose groups, all of the guinea pigs developed lesions with mean peak lesion scores ranging from recovered from the vagina was significantly less in animals inoculated with RAV 9395 than HSV-2(G), as exhibited in 2.4 to 4.2. The results of this study showed that a dose of 1 1 10 5 pfu HSV-2(G) produced a 100% infection rate, high both virus titer -day AUC and mean peak titer. The neutralizing antibody response elicited by ivag inoculation of RAV 9395 significant, they were only 1.
-2 logs lower than those of HSV-2(G). was Ç5-fold lower than that elicited by HSV-2(G). A contributing factor to the lower neutralizing antibody titers elicited by
Of the 15 animals that were inoculated ivag with 1 1 10 6 pfu RAV 9395, 12 were infected, and only 1 of the 15 guinea RAV 9395 may be the significant reduction in vaginal RAV 9395 replication titers. It should be noted, however, that alpigs developed HSV genital lesions, with a lesion score of 0.1, indicating an extremely mild erythema (table 4) . In this cohort, though the reduced vaginal replication titers were statistically with HSV-2(G) exhibited severe lesions, with a mean peak lesion score of 3.0, indicating at least half of the genital area was covered with coalesced HSV-2 lesions. There were no recurrences in any of the animals inoculated with RAV 9395 after day 21, whereas 4 animals inoculated with HSV-2(G) showed recurrences over the 28-day observation period.
Neutralizing antibody titers were detected in serum samples from all animals inoculated with RAV 9395, and the titers rose during the 57 days of the experiment (data not shown). Latent virus was reactivated from only 1 of the 6 animals inoculated with RAV 9395 following cocultivation of explanted ganglia, whereas latent virus was recovered from 6 of 7 animals inoculated with HSV-2(G). The identity of all reactivated viruses was confirmed by restriction enzyme analyses. the end of the study. The severity and duration of primary disease was monitored by examination of the animals daily for 28 days after challenge for typical HSV-2 genital lesions. Blood samples were obtained as described above from all animals for 12 of 15 animals appeared to have no visible signs of HSV-2 determination of serum neutralizing antibody titers. At postvacdisease, although they clearly had shedding of infectious virus cination day 62, the lumbosacral ganglia were aseptically reconfirmed as RAV 9395, albeit at reduced titers compared with moved, and the presence of latent virus was detected by reacti-HSV-2(G) recovered from infected animals. Consistent with the dose-range study (table 3), 13 of 15 animals inoculated vation in vitro. NOTE. AUC Å area under curve. P values for both virus titer -day AUC and mean peak virus titer for RAV 9395 were .001 for both symptomatic animals and total animals. P values for both lesion-day AUC and mean peak lesion score for RAV 9395 were õ.001 for both symptomatic animals and total animals.
The results presented in table 5 show that immunization with Examination of the symptomatic animals alone for lesionday AUC (not shown) or mean peak lesion score did not change RAV 9395 did not prevent shedding of the challenge virus. Nevertheless, in the group that received the highest dose of the interpretation of the protection data. P values for the lesion scores in the symptomatic animals remained highly significant RAV 9395 (5 1 10 6 pfu) there was a significant decrease in virus titer, indicating impaired replication of the challenge virus at all doses except for 1 1 10 4 pfu (data not shown). All mean neutralizing antibody titers were õ10 before imor more efficient viral clearance following vaccination with RAV 9395. No shedding of infectious virus was detected from munization and increased to Ç200 after immunization with RAV 9395. After challenge with HSV-2(G), they increased 10 days after challenge throughout the remainder of the experiment. The development and severity of lesions was signifianother 4-to 15-fold (range of titers, 700 -2800). The boost in neutralizing titers following challenge with HSV-2(G) was cantly reduced by vaccination with RAV 9395 (table 5) . Lesion-day AUC and mean peak lesion scores were both greater in animals that received higher vaccine doses and greater than in animals inoculated with HSV-2(G) alone (data substantially lower in groups vaccinated with RAV 9395 at doses of 1 1 10 5 pfu and above. Mean lesion scores in these not shown). There was no correlation between the neutralizing antibody titers induced by immunization with RAV 9395 and groups were minimal, ranging from 0.5 to 0.9 when the entire cohort of immunized animals was considered. Only very mild protection measured by vaginal virus titers. There was also no significant dose-response of HSV neutralizing antibody titers erythema was seen in some of the animals. In animals vaccinated with medium alone, greater than half of the area examafter immunization with RAV 9395. Nevertheless, there was a trend toward reduction of mean peak lesion score with increasined was covered with coalesced lesions and some ulceration; their mean lesion score was 3.8.
ing neutralizing antibody titers after challenge. models tested, it was overattenuated in humans and therefore of little utility as a human vaccine [23, 45, 46] . R7020 has a 500-bp deletion in the tk gene and a 14-kbp deletion extending from the a27 gene (UL54) in the unique The results of the reactivation experiments are summarized in table 6. Latent virus was recovered following cocultivation long segment of the genome across the internal inverted repeats to the a4 promoter regulatory domain in the unique short segof sacral ganglia from 5 of 5 animals immunized with medium alone (animal 768 was not included in the analysis, as it was ment of the viral genome. Into this genetically engineered HSV-1 backbone, an HSV-2(G) DNA fragment encoding subsequently shown to be uninfected) and 5 of 6 animals immunized with the lowest dose of RAV 9395 (1 1 10 4 pfu). Latent HSV-2 glycoproteins D, G, I, and a truncated form of E was inserted, together with an intact tk gene. Therefore, our goal virus was recovered from only 1 of 6 animals in the 2 groups that were immunized with either 1 1 10 5 pfu of RAV 9395 or was to produce a safe, more effective, less attenuated type 2 vaccine candidate combining specific deletions embodied in 1 1 10 6 pfu of RAV 9395 (SPGA). In the group receiving 1 1 10 6 pfu of RAV 9395 (medium), 2 of 6 animals were R7020 with the deletion of both copies of the g 1 34.5 gene. Inoculation (ivag) of weanling guinea pigs with HSV-2 repositive for reactivated virus. No reactivated virus was recovered from the ganglia of 6 of 6 guinea pigs immunized with 5 sults in a primary genital infection characterized by initial replication of virus in the vaginal tract, followed by the development 1 10 6 pfu of RAV 9395 (SPGA). All the latent, reactivated viruses were the challenge virus HSV-2(G), as determined by of external vesicular lesions. High titers of virus are detected in the vaginal tract 1 -3 days after infection; they gradually restriction enzyme digestion followed by Southern blot analysis and polymerase chain reaction with the appropriate primers to clear within 7 -10 days. The genital lesions first appear on day 4, peak lesion severity occurs on days 10 -12, and the lesions distinguish RAV 9395 from HSV-2(G) in the reactivated ganglia samples. These results taken together with the results of generally heal by days 18 -20. After resolution of the primary disease, spontaneous recurrent vesicular lesions appear on the the virulence study indicate that RAV 9395 either established latency at a significantly lower level than did HSV-2(G) or external genital skin. Throughout the course of the primary infection, urinary retention and paralysis of the hind limbs are that RAV 9395 established latency but was unable to reactivate efficiently. In addition, immunization with RAV 9395 at doses not uncommon and death can occur, usually by spread of the virus to the CNS. of 1 1 10 5 pfu and above may preclude the establishment of latency by the challenge virus HSV-2(G). In our study, RAV 9395 was cleared rapidly from the vaginal tract of the guinea pig and in 14 of 15 animals produced no genital lesions immunization with a single dose of 1 1 10 5 pfu of RAV 9395 protected guinea pigs from significant HSV disease following when administered ivag at a dose of 1 1 10 6 pfu. Of the 15 infected animals, 1 showed extremely mild erythema in the challenge with 1 1 10 5 pfu of HSV-2(G). genital area. Similar results were previously reported with the prototype type 1 vaccine candidate, R7020, at doses of Discussion 1 1 10 5 and 1 1 10 8 pfu [23] . Generally, establishment of latent infection by RAV 9395 was inefficient inasmuch as inHere we have described the construction of a recombinant virus, designated RAV 9395, designed to function as a potential fectious virus could be reactivated in only 1 of 6 animals by cocultivation of the sensory ganglia in the virulence study. In live HSV-2 vaccine. The aim was to attenuate the low-passage strain HSV-2(G) by introducing a series of specific gene delethe virulence and the protection studies combined, only 1 of 36 ganglia samples from animals vaccinated with RAV 9395 tions (g 1 34.5, UL55, and UL56) in the viral genome. The choice of genes to delete was based on two major observations. cocultivated by explant culture yielded infectious RAV 9395.
In the virulence study, there were no recurrences of vaginal First, HSV-1 recombinant viruses with deletions or interrup-JID 1998;177 (May) lesions in any of the animals inoculated with RAV 9395. In All of the structural proteins apart from the deleted one of the DISC viruses are available to stimulate a humoral response, contrast, animals inoculated with 1 log lower dose of HSV-2(G) had recurrent genital lesions, and latent virus was reactiand as all these viral antigens are synthesized de novo, they can be presented in the context of class I molecules to stimulate a vated from 6 of the 7 surviving infected animals.
The results from the protection and virulence studies suggest cytotoxic T lymphocyte response. In addition, because the DISC viruses are infectious, they can be administered by a route dethat the ability of RAV 9395 to reactivate has been greatly reduced. This phenotype is a desirable feature for an HSV signed to stimulate a local immune response against natural infection [25] . It has been reported that DISC virus vaccines vaccine candidate and is likely linked to the inability of RAV 9395 to express the g 1 34.5 gene product. Reduced reactivation derived from HSV-1 can protect guinea pigs from initial severe primary disease after HSV-2 challenge. More than one dose of rates have also been observed with a type 1 HSV mutant harboring a deletion in the ORF [13, 16] .
vaccine was required to afford this protection, and vaccination with DISC HSV-1 virus was unable to prevent subsequent recurAnimals vaccinated with 1 1 10 4 pfu of RAV 9395 did not show a significant reduction in development or severity of rent HSV-2 disease in these same animals [25] . In our RAV 9395 virulence study, no recurrences were dethe lesions caused by the challenge virus. A sharp contrast was detected in the levels of protection between 1 1 10 4 and tected in any of the animals after day 21, the cutoff point for the establishment of latency in the guinea pig model. The ani-1 1 10 5 pfu vaccinating doses. From this, we hypothesize that a threshold of viral replication may be required to stimulate mals were monitored for a total of 56 days, and on day 21, 1 of the animals did show a distinct erythema with a lesion score the protective functions of the host immune system, to prevent significant HSV disease and latent infection of the sensory of 0.5. In the challenge study, with the higher immunizing doses (1 1 10
5
, 1 1 10 6 , and 5 1 10 6 pfu), there was reduced ganglia. Of interest, in most cases, latent challenge virus could not be reactivated from the spinal ganglia of animals vaccinated recurrence severity after day 21. The range of mean lesion scores was 0.0 -0.3, indicative of slight erythema after day 21; with the higher concentrations of RAV 9395. One interpretation of these observations is that the vaccinating virus colonizes the however, the animals were only monitored for 28 days. Recently, it has been reported that HSV-2 -based DISC viral sensory ganglia more efficiently at higher inoculating doses and precludes latent infection of the same ganglia by a subsequent vaccines can also protect guinea pigs against genital herpes after HSV-2 challenge. It is difficult to compare our results challenge virus. If true, this latter explanation may account for the observation that superinfection of individuals already with those from the single dose of DISC viral vaccine without a direct comparison. However, higher concentrations of DISC seropositive for HSV-2 by other HSV strains are rare. The ability of RAV 9395 to prevent colonization of the sensory vaccine (from 1 1 10 6 to 1 1 10 7 pfu) administered in two doses appear to elicit high levels of protection [28] . ganglia by the wild-type challenge virus represents another desirable attribute for an HSV-2 vaccine.
The DISC viruses, although safer vaccine candidates, may not be able to stimulate the immune system as effectively as Comparable levels of protection against challenge with HSV-2 viruses in the guinea pig model with subunit vaccines the live attenuated viruses, which can undergo continued replication in the host. Potentially higher doses of DISC viruses has been reported [21, 27, 47] . In these reports, adjuvanted HSV glycoproteins gD and gB or mixtures of lectin-purified would be required; this may limit their utility as potential vaccines in humans, as they would have to be grown to signifi-HSV-1 and -2 glycoproteins from infected cells were formulated as subunit vaccines. Although RAV 9395 has not been cantly higher titers, and reactogenicity problems may arise in the host, due to administration of high loads of viral antigens. directly compared with the glycoprotein subunit vaccine in the same set of experiments, it should be noted that a single dose Another disadvantage of the use of DISC viral vaccines is the possibility that homologous recombination between sequences of RAV 9395 protected animals from HSV-2 disease after an HSV-2 challenge, whereas three doses of the subunit vaccines in the virus with HSV sequences in the complementing cell line could lead to the functional reconstruction of the deleted containing a mixture of several HSV glycoproteins were required to achieve a similar level of protection. It would be viral gene and subsequent full virulence. Although these recombination events maybe rare [52] , for clinical use, it is essential interesting to know the level of protection afforded by a single dose of HSV glycoprotein vaccine.
that the mutant DISC virus and the complementing cell line have no sequences in common promoting recombination. Viruses containing deletions in genes essential for growth in tissue culture systems are under development as vaccine Finally, in recent human clinical trials, subunit vaccines containing mixtures of HSV-2 glycoproteins gB and gD together candidates [48 -51] . These viruses, termed DISC (disabled infectious single cycle) viruses, are capable of only one round with MF59 adjuvant showed no prophylactic and little therapeutic utility as vaccines for HSV-2 infection and recurrence, of viral replication and have several features that make them attractive vaccine candidates. They are generally considered respectively [53] . The failure of the HSV subunit vaccines clearly suggests safer than live attenuated viruses, as they are unable to spread within the vaccinated host.
that an alternative strategy is required to develop a successful
